Prior to joining Maclean Health as Head of the MacleanRx Division, Mr. Ley successfully introduced and expanded use for more than 50 innovator FDA approved large and small molecule pharmaceuticals including specialty, orphan, ultra-orphan, buy-and-bill, while developing, leading, and implementing each pharmaceutical organization’s national strategy and presence throughout the Veterans Health Administration, Department of Defense and TRICARE, the Indian Health Services, and each State Medicaid Program.